Amsterdam, The Netherlands, November 3, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for an oral presentation at the 58th Annual Meeting in San Diego, California on December 5, 2016.
The abstract will be presented by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and one of the principal investigators for the trial, and will provide one year data from Kiadis Pharma’s international multi-center study, in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), have been enrolled to be treated with ATIR101™ as part of their transplant regimen. In addition, the abstract includes a comparison to a historic control group.
Abstract title: Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL
Date: Monday, December 5, 2016 from 6:15 to 7:45 PM Eastern Daylight Time (EDT) (presentation time: 6:30 PM EDT)
Publication: 1226
Session: 711. Cell Collection and Processing: Immunotherapy, Immunomodulation and Immune Reconstitution
Location: San Diego Convention Center, Room 30
The full abstract is available to view online at www.hematology.org later today at 9:00 AM EDT. In addition, the abstract will be published online in the December 1, 2016 supplemental volume of Blood.
